Page 50 - CSIR-IGIB Annual Report 2020-21
P. 50
inhibitors were studied in vitro through CDK5 three inhibitors showed reduction in CDK5
kinase assay inhibition and the best of 8 hyper-activity as well as the least cell toxicity.
compounds were selected for further studies. The inhibitors will be further studied in vivo by
The aim of these studies is to identify inhibitors treatment in T2D mice models and its rescue in
of CDK5 deregulation or hyperactivity. Next cognitive impairment through behavioral
level functional screening was performed, and studies.
Publications
WilsonGen a comprehensive clinically annotated genomic variant resource for Wilson's Disease. Kumar M,
Gaharwar U, Paul S, Poojary M, Pandhare K, Scaria V, Bk B. Sci Rep. 2020 Jun 3;10(1):9037.
ATP7A Clinical Genetics Resource - A comprehensive clinically annotated database and resource for genetic
variants in ATP7A gene. Mhaske A, Dileep KV, Kumar M, Poojary M, Pandhare K, Zhang KYJ, Scaria V, Binukumar
BK. Comput Struct Biotechnol J. 2020 Sep 2;18:2347-2356.
The Indian Collaborative Research on Wilson’s Disease - an effort to understand the genetic epidemiology of
Wilson's Disease in India. Binukumar BK, ICROWD Consortium. Transl Genomics Vol. 1 No. 1 (2020).
Annual Report 2020-21 47
